Cepheid Q2 Revenues Climb 21 Percent, but Miss Analyst Estimates | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid's revenues grew 21 percent year over year during the second quarter, the Sunnyvale, Calif.-based firm reported after the close of the market on Thursday.

For the three months ended June 30, total revenues came in at $81.0 million, compared to $67.0 million a year ago. Wall Street analysts had expected revenues of $82.7 million.

Pacing revenue growth was reagent and disposable sales growth to $63.9 million from $49.5 million a year ago, a 29 percent increase. System sales increased 3 percent to $14.5 million from $14.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.

DuPont teams with genome editing firm Caribou Biosciences for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.